Gigoux, M., Zappasodi, R., Park, J., Pourpe, S., Ghosh, A., Bozkus, C. C., … Merghoub, T. (2020). 444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. In Regular and young investigator award abstracts (p. A270.1-A270). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2020-sitc2020.0444

Gigoux, Mathieu, Roberta Zappasodi, Joseph Park, Stephane Pourpe, Arnab Ghosh, Cansu Cimen Bozkus, Levi Mangarin, et al. “444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination.” In Regular and Young Investigator Award Abstracts, A270.1-A270. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0444.

Gigoux M, Zappasodi R, Park J, Pourpe S, Ghosh A, Bozkus CC, et al. 444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. In: Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020. p. A270.1-A270.

Gigoux, Mathieu, et al. “444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2020, p. A270.1-A270. Crossref, doi:10.1136/jitc-2020-sitc2020.0444.

Gigoux M, Zappasodi R, Park J, Pourpe S, Ghosh A, Bozkus CC, Mangarin L, Redmond D, Verma S, Schad S, Duke W, Jan M, Leventhal M, Ho V, Hobbs G, Knudsen TA, Skov V, Kjær L, Larsen TS, Hansen DL, Coleman Lindsley R, Hasselbalch H, Grauslund J, Andersen M, Holmström M, Chan T, Rampal R, Abdel-Wahab O, Bhardwaj N, Wolchok J, Mullally A, Merghoub T. 444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020. p. A270.1-A270.